MARKET

CNCE

CNCE

Concert Pharm
NASDAQ
4.990
-0.090
-1.77%
After Hours: 5.08 +0.09 +1.80% 16:05 11/28 EST
OPEN
5.00
PREV CLOSE
5.08
HIGH
5.10
LOW
4.851
VOLUME
215.64K
TURNOVER
0
52 WEEK HIGH
7.37
52 WEEK LOW
2.570
MARKET CAP
239.21M
P/E (TTM)
-1.7027
1D
5D
1M
3M
1Y
5Y
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
MELBOURNE, Australia, November 21, 2022--The presentation includes new analyses on the effect of baseline severity and duration of current episode of hair loss on scalp hair regrowth.
Business Wire · 11/21 12:00
Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
LEXINGTON, Mass., November 09, 2022--Concert will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022.
Business Wire · 11/09 12:00
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/08 10:00
Concert Pharma falls 13% after third quarter results
Seekingalpha · 11/07 16:45
BRIEF-Concert Pharmaceuticals Reports Q3 Loss Per Share Of $0.58
Reuters · 11/07 12:40
Concert Pharma: Q3 Earnings Insights
Benzinga · 11/07 12:16
Concert Pharma GAAP EPS of -$0.58 beats by $0.01, revenue of $0.08M in-line
Seekingalpha · 11/07 12:12
Concert Pharmaceuticals Q3 EPS $(0.58) Up From $(0.78) YoY, Sales $8.00K Down From $543.00K YoY
Benzinga · 11/07 12:02
More
About CNCE
Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The Company is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The Company is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.

Webull offers kinds of Concert Pharmaceuticals Inc stock information, including NASDAQ:CNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNCE stock methods without spending real money on the virtual paper trading platform.